“Am I understanding the PR correctly that with a
Post# of 148190
The mild/moderate trial in the U.S. will most likely be complete and public before the Mexico trial is competed. If the data from mild/moderate trial shows efficacy, the the 30 patient trial in Mexico shows efficacy, I can see Mexico approving the drug for use. Especially if the FDA approved leronlimab for COVID19 following release of the mild/mod COVID19 data.